Search Results for 'von Willebrand Disease;'
BAXTER PRESENTS PRECLINICAL DATA AT ISTH ON ITS INVESTIGATIONAL COMPOUND BAX 499 FOR POTENTIAL SUBCUTANEOUS HEMOPHILIA THERAPY AND FINAL PHASE I DATA ON RECOMBINANT VON WILLEBRAND FACTOR
FOR IMMEDIATE RELEASE Media Contacts Doreen Eaton, (805) 372-3417 Marie Kennedy, (805) 372-3543 Investor Contacts Mary Kay Ladone, (847) 948-3371 Clare Trachtman, (847) 948-3085 BAXTER PRESENTS PRECLINICAL DATA AT ISTH ON ITS INVESTIGATIONAL COMPOUND BAX 499 FOR POTENTIAL SUBCUTANEOUS HEMOPHILIA THERAPY AND FINAL PHASE I DATA ON RECOMBINANT VON WILLEBRAND FACTOR Three Baxter Scientists Granted […]
FOR IMMEDIATE RELEASE FDA Approves Revised Alphanate® Labeling to Include Reduced Infectivity of an Experimental Model Agent for vCJD Alphanate® is the first plasma-derived blood clotting factor to include labeling statements on manufacturing processes that provide a reasonable assurance of removal for low levels of a variant Creutzfeldt-Jakob disease (vCJD) model agent. Barcelona, Spain (March […]
Link to article September 1, 2010 (Cincinnati, Ohio) BioRx and Hemophilia of North Carolina announce the availability of four 2011 BioRx Educational Scholarships in the amount of $2,000 each to individuals with bleeding disorders. The scholarships will be awarded for the 2011-2012 school year, and the deadline for submitting applications is May 1, 2011. BioRx […]
Assisting and Advocating for the Bleeding Disorders Community